Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Ibrahim Aldoss ,Hematology Tissue Bank ,Division Of Leukemia ,Leukemia Research ,Department Of Hematology ,Gehr Family Center ,Hematopoietic Cell Transplantation ,Leukemia Registry ,Hematologic Oncology ,Onclive Tv ,City Of Hope ,